Ilyang Pharmaceutical Co.,Ltd Stock price

Equities

A007570

KR7007570005

Pharmaceuticals

End-of-day quote Korea S.E. 07:00:00 2024-03-26 pm EDT 5-day change 1st Jan Change
14,570 KRW -1.22% Intraday chart for Ilyang Pharmaceutical Co.,Ltd +2.32% -6.90%
Sales 2022 384B 284M Sales 2023 371B 274M Capitalization 281B 208M
Net income 2022 19.24B 14.24M Net income 2023 -2.55B -1.88M EV / Sales 2022 0.97 x
Net Debt 2022 20.7B 15.32M Net Debt 2023 65.35B 48.36M EV / Sales 2023 0.94 x
P/E ratio 2022
18.7 x
P/E ratio 2023
-112 x
Employees 655
Yield 2022
0.78%
Yield 2023
0.96%
Free-Float 66.03%
More Fundamentals * Assessed data
Dynamic Chart
Tranche Update on Ilyang Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on April 6, 2023. CI
Ilyang Pharmaceutical Co.,Ltd's Equity Buyback announced on April 6, 2023, has expired with 115,080 shares, representing 0.63% for KRW 1,999.72 million. CI
Tranche Update on Ilyang Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on April 6, 2023. CI
Ilyang Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Ilyang Pharmaceutical Co.,Ltd announces an Equity Buyback for KRW 2,000 million worth of its shares. CI
Ilyang Pharmaceutical Co.,Ltd authorizes a Buyback Plan. CI
Tranche Update on Ilyang Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on March 10, 2022. CI
Ilyang Pharmaceutical Co.,Ltd's Equity Buyback announced on March 10, 2022, has expired with 118,321 shares, representing 0.65% for KRW 2,859.89 million. CI
Eight South Korean Firms to Donate $2.4 Million Worth of Medicine to Ukraine MT
Ilyang Pharmaceutical Co.,Ltd announces an Equity Buyback for KRW 3,000 million worth of its shares. CI
Ilyang Pharmaceutical Co.,Ltd authorizes a Buyback Plan. CI
Ilyang Pharmaceutical Co.,Ltd(KOSE:A007570) dropped from KOSPI 200 Index CI
Boryung Pharmaceutical : S.Korea sticks to flu vaccine plan despite safety fears after 25 die RE
Boryung Pharmaceutical : Number of South Koreans dying after flu shot rises, prompts vaccine worries RE
Il-Yang Pharmaceutical Signs Licence with Laboratorios Biopas to Export Leukemia Drug Supect to Colombia CI
More news
1 day-1.22%
1 week+2.32%
Current month+2.61%
1 month+2.32%
3 months-5.57%
6 months+4.07%
Current year-6.90%
More quotes
1 week
14 270.00
Extreme 14270
14 970.00
1 month
13 900.00
Extreme 13900
14 970.00
Current year
13 900.00
Extreme 13900
16 080.00
1 year
13 130.00
Extreme 13130
18 430.00
3 years
13 130.00
Extreme 13130
45 650.00
5 years
13 130.00
Extreme 13130
106 500.00
10 years
13 130.00
Extreme 13130
106 500.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 73 -
Director/Board Member 66 -
Director/Board Member 47 -
Members of the board TitleAgeSince
Director/Board Member 47 -
Chief Executive Officer 73 -
Director/Board Member 66 -
More insiders
Date Price Change Volume
24-03-27 14,570 -1.22% 22,667
24-03-26 14,750 -1.27% 41,233
24-03-25 14,940 +2.40% 85,032
24-03-22 14,590 +2.10% 50,006
24-03-21 14,290 +0.35% 18,644

End-of-day quote Korea S.E., March 26, 2024

More quotes
ILYANG PHARMACEUTICAL CO.,LTD is a Korea-based company principally engaged in the manufacture and distribution of pharmaceutical products. The Company mainly manufactures and sells pharmaceutical products including prostatitis agents, anti-inflammatory drugs, diabetic agents, gastritis agents, and others. The Company also produces products including nourishing tonics and health supplements, among others.
More about the company
  1. Stock
  2. Equities
  3. Stock Ilyang Pharmaceutical Co.,Ltd - Korea S.E.